Challenges and future outlook in the management of the diabetic foot
The MolecuLight i:X was recently featured in a timely invited review article discussing the current challenges and future outlook in the management of diabetic foot. As many of us know, diabetic foot ulcers, are a serious health problem in our society today. People with diabetes have a 25% chance of developing a diabetic foot ulcer in their lifetime.
Among the various clinical wound assessment methods employed today, the following were discussed in the article published in the Journal Diabetic Medicine: visualization of bacteria, temperature, oxygen saturation, skin perfusion and wearable technology as they relate to diabetic wound care.
The authors discuss that incorporating the MolecuLight i:X into wound care protocols may help address the ever-increasing battle against antibiotic resistance and supports an objective means toward improving antibiotic stewardship.
With the MolecuLight i:X, clinicians are given real-time visual information, at the point-of-care, to aid in the assessment and documentation of wounds.3 When combined with clinical best practice, fluorescence imaging of wounds offers clinicians real-time information on bacterial presence and distribution.1,2 This can guide early interventions to reduce bioburden and promote wound healing while decreasing wound care costs associated with delayed wound healing and ineffective treatments.1,3
Click link below to see full article:
‘New horizons in the understanding of the causes and management of diabetic foot disease: report from the 2017 Diabetes UK Annual Professional Conference Symposium.’